NEUP Neuphoria Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why NEUP matters now
Neuphoria Therapeutics Inc. (NEUP) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.54 with +0.85% on the session and $19.1M in market capitalization; recent performance reads 1-month -9.64% and YTD +11.08%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-505.1K, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 255.3%.
The latest indexable market news headline is "Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Ryan Jane filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.79
P/S
-2.22
EV/EBITDA
-0.17
DCF Value
$50.36
FCF Yield
255.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
104.7%
Operating Margin
250.0%
Net Margin
263.1%
ROE
-109.7%
ROA
-79.2%
ROIC
-77.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-505.1K | $-0.09 |
| Q2 2026 | $0.00 | $2.8M | $-0.77 |
| Q1 2026 | $0.00 | $-15.0M | $-6.67 |
| Q4 2025 | $-10.5M | $-14.9M | $-4.65 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Exchange
—
Beta
0.72
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.